Many different diseases fall under the umbrella of cardiovascular disease, and the causes range from structural defects to infection, inflammation, environmental and genetics. As a result, cardiovascular drug development programs are complex and often require multidisciplinary research.
Charles River understands the challenges associated with developing a drug, biologic or device for the prevention or treatment of cardiovascular diseases, as well as the importance of assessing potential undesirable cardiac effects for any new compound regardless of the disease target or condition. We have a long history of providing a multitude of products and services through our Research Models and Preclinical Services businesses to support you from early discovery to market.
Products & Services
- Preclinical cardiovascular screening and profiling
- Conscious and anesthetized models
- Telemetry
- Dedicated surgical suites
- In vitro and in vivo assessments
- Research disease models
- hERG assay
- Echocardiography
- Fluoroscopy
- Safety and efficacy studies
- Standard and specialized routes of administration
- Formulation development, preparation, and analysis
- Pathology services
- Scientific and regulatory consulting
Related Information
Article: Minimizing Cardiovascular Liabilities Throughout Drug [Development Drug Delivery Technology (October 2009, Vol. 9, No. 9)]
Article: Guarding the Heart [Drug Discovery & Development (June 2009, Vol. 12, No. 6)]
Webinar Replay: When Drugs Have Heart Attacks (June 2009)
Webinar Replay: The Cardiovascular System and Drug Development
(March 2009)